-- Ilian Cori, Bulgaria, photography
-- Diego Constantino Sossa Centurion, Argentina, essay
All contest submissions will be on display at the World Congress and will appear at events around the world in 2008.
Bayer is committed to developing innovative hemophilia A treatments and
expanding scientific and clinical knowledge that improves patient care.
Over the past two decades, Bayer has:
-- Invested hundreds of millions of dollars in hemophilia research,
clinical trials and post-marketing studies to ensure the safety and
efficacy of its Kogenate(R) products.
-- Supported local and international hemophilia patient groups such as the
WFH in their advocacy and patient care initiatives.
-- Supported innovative educational and training programs to improve the
diagnosis and care of people with bleeding disorders around the world.
-- Donated more than 30 million international units of product to
countries with limited access to hemophilia treatment, bringing hope
and saving lives.
About Kogenate(R) FS
Kogenate(R) FS (Antihemophilic Factor [Recombinant]) is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate(R) FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate(R) FS. Please see the full prescribing information for important risk and use information at http://www.kogenatefs.com.
About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classic
hemophilia, is largely an inherited bleeding disorder in which one of the
proteins needed to form blood clots
|SOURCE Bayer HealthCare|
Copyright©2008 PR Newswire.
All rights reserved